References
- Law RM, Ngo MA, Maibach HI. Twenty clinically pertinent factors/observations for percutaneous absorption in humans. Am J Clin Dermatol 2020;21:85–95.
- Wester RC, Maibach HI. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. Drug Metab Rev 1983;14:169–205.
- Ngo MA, O’Malley M, Maibach HI. Percutaneous absorption and exposure assessment of pesticides. J Appl Toxicol 2010;30:91–114.
- Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967;48:181–183.
- Guy R, Maibach HI. Calculations of body exposure from percutaneous absorption data. In: Bronaugh RL, Maibach HI, eds. Topical absorption of dermatological products. New York, NY: Marcel Dekker; 2002: 311–315.
- Azike JE. A review of the history, epidemiology and treatment of squamous cell carcinoma of the scrotum. Rare Tumors 2009;1:e17.
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm [last accessed 28 Apr 2020].
- Lev-Tov H, Maibach HI. Regional variations in percutaneous absorption. J Drug Derm 2012;11:e48–e51.
- Britz MB, Maibach HI, Anjo DM. Human percutaneous penetration of hydrocortisone: the vulva. Arch Dermatol Res 1980;267:313–316.
- Oriba HA, Bucks DAW, Maibach HI. Percutaneous absorption of hydrocortisone and testosterone on the vulva and forearm: effect of the menopause and site. Br J Dermatol 1996;134:229–233.
- Rougier A, Lotte C, Corcuff P, et al. Relationship between skin permeability and corneocyte size according to anatomic site, age, and sex in man. J Soc Cosmet Chem 1988;39:15–26.
- Maibach HI, Feldmann RJ, Milby TH, et al Regional variation in percutaneous penetration in man. Arch Environ Health 1971;23:208–211.
- VanRooij JGM, De Roos JHC, Bodelier-Bade MM, et al. Absorption of polycyclic aromatic hydrocarbons through human skin: differences between anatomical sites and individuals. J Toxicol Environ Health 1993;38:355–368.
- NIH National Medical Library PubChem [Internet]. Available from: https://pubchem.ncbi.nlm.nih.gov [last accessed 28 Apr 2020].
- Dugheri S, Bonari A, Gentili M, et al. High-throughput analysis of selected urinary hydroxy polycyclic aromatic hydrocarbons by an innovative automated solid-phase microextraction. Molecules 2018;23:1869.
- Rougier A, Dupuis D, Lotte C, et al. Regional variation in percutaneous absorption in man: measurement by the stripping method. Arch Dermatol Res 1986;278:465–469.
- Lotte C, Rougier A, Wilson DR, et al. In vivo relationship between transepidermal water loss and percutaneous penetration of some organic compounds in man: effect of anatomic site. Arch Dermatol Res 1987;279:351–356.
- Tsai JC, Lin CY, Sheu HM, et al Noninvasive characterization of regional variation in drug transport into human stratum corneum in vivo. Pharm Res 2003;20:632–638.
- Tsai JC, Lu CC, Lin MK, et al. Effects of sebum on drug transport across the human stratum corneum in vivo. Skin Pharmacol Physiol 2012;25:124–132.
- Shah AK, Wei G, Lanman RV, et al. Percutaneous absorption of ketoprofen from different anatomical sites in man. Pharm Res 1996;13:168–172.
- NCI thesaurus [Internet]. National Cancer Institute. Available from: https://ncit.nci.nih.gov/ncitbrowser/pages/home.jsf?version=20.05d [last accessed 7 Jun 2020].
- Abrams LS, Skee DM, Natarajan J, et al Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites . Br J Clin Pharmacol 2002;53:141–146.
- DAYTRANA® (methylphenidate transdermal system): Highlights of Prescribing Information [Internet]; [p. 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021514s011lbl.pdf [last accessed 7 Jun 2020].
- Lefevre G, Sedek G, Huang HL, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007;47:471–478.
- Elshoff J-P, Braun M, Andreas J-O, et al. Steady-state plasma concentration profile of transdermal rotigotine: An integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34:966–978.
- SECUADO® (asenapine) Transdermal system: Highlights of Prescribing Information [Internet]; [p. 22]. Available from; https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212268s000lbl.pdf#page22 [last accessed 7 Jun 2020].
- EMSAM® (Selegiline Transdermal System) [Internet]; [p. 2]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021336s000_021708s000_PRNTLBL.pdf [last accessed 7 Jun 2020].
- FDA Summary Basis of Approval: Asenapine. FDA study HP-3070-US-03 [Internet]; [p. 64-65]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212268Orig1s000MultidisciplineR.pdf [last accessed 28 Apr 2020].
- FDA Summary Basis of Approval: Buprenorphine. FDA Study BP96-0501 [Internet]; [p. 94,121–122]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021306Orig1s000ClinPharmR.pdf [last accessed 28 Apr 2020].
- McGregor TR, Matzek KM, Keirns JJ, et al. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther 1985;38:278–284.
- Ebihara A, Fujimura A, Ohashi K, et al. Influence of application site of a new transdermal clonidine, M-5041T, on its pharmacokinetics and pharmacodynamics in healthy subjects. J Clin Pharmacol 1993;33:1188–1191.
- FDA Summary Basis of Approval: Fentanyl. FDA study C-2002-047 [Internet]; [p. 235–236]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/019813Orig1s044.pdf [last accessed 28 Apr 2020].
- Sobue S, Sekiguchi K, Kikkawa H, et al. Effect of application sites and multiple doses on nicotine pharmacokinetics in healthy male Japanese smokers following application of the transdermal nicotine patch. J Clin Pharmacol 2005;45:1391–1399.
- Gonzalez MA, Campbell D, Rubin J. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:227–232.
- FDA Summary Basis of Approval: Methylphenidate. FDA study 17-012. [Internet]; [p. 35]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021514s000_ClinPharmR_P2.pdf [last accessed 28 Apr 2020].
- Solassol I, Caumette L, Bressolle F, et al. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep 2005;14:1029–1036.
- Hochel J, Schuett B, Ludwig M, et al. Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study. Int J Clin Pharmacol Ther 2014;52:856–866.
- Stanczyk FZ, Archer DF, Rubin A, et al. Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. Contraception 2013;87:744–749.
- Taggart W, Dandekar K, Ellman H, et al. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara). Menopause 2000;7:364–369.
- Zobrist RH, Quan D, Thomas HM, et al. Pharmacokinetics and metabolism of transdermal oxybutynin: In vitro and in vivo performance of a novel delivery system. Pharm Res 2002;20:103–109.
- Yu Z, Gupta SK, Hwang SS, et al. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. J Clin Pharmacol 1997;37:1129–1138.
- PrEVRA®. Product Monograph [Internet]. [cited 2020 Apr 28]; [p. 46]. Available from: https://s3.pgkb.org/attachment/Norelgestromin_and_ethinyl_estradiol_HCSC_06_03_15.pdf [last accessed 28 Apr 2020].
- FDA Summary Basis of Approval: Selegiline. FDA studies 0052, 9806, and 96B. [Internet]; [p. 32]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021336s000_021708s000_ClinPharmR_Part1.pdf [last accessed 28 Apr 2020].
- Tur E, Maibach HI, Guy RH. Percutaneous penetration of methyl nicotinate at three anatomic sites: Evidence for an appendageal contribution to transport? Skin Pharmacol 1991;4:230–234.
- Leskur D, Bukić J, Petrić A, et al Anatomical site differences of sodium lauryl sulfate-induced irritation: randomized controlled trial. Br J Dermatol 2019;181:175–185.
- Wester RC, Buck DAW, Maibach HI. Human in vivo percutaneous absorption of pyrethrin and piperonyl butoxide. Food Chem Toxicol 1994;32:51–53.
- Elmady A, Hui X, Maibach HI. Role of hair follicle in penetration and decontamination. Forthcoming.